Non-Antibody Products — page 1 of 22,655
Non-Antibody Products
Page 1 of 22,655
| Name | Description | Size | Catalog # | Supplier | |
|---|---|---|---|---|---|
| A-366 | Purity ≥98% by HPLC. Background: A-366 is a potent and selective G9a /… | 1 mg, 5 mg | MBS842453 |
 MYBIOSOURCE INC. |
More Info |
| A-366 | Purity ≥98%. MW: 329.444 | 100 mg, 500 mg | MBS131198 |
MYBIOSOURCE INC. |
More Info |
| A-366 | Purity >98%. A-366 is a potent and selective G9a / GLP histone lysine meth… | 10 mg, 25 mg, 50 mg | MBS384085 |
MYBIOSOURCE INC. |
More Info |
| A427 | A427 cells are derived from human lung epithelial carcinoma taken from a 5… | 0.1 mg, 0.2 mg, 0.5 mg | MBS201043 |
MYBIOSOURCE INC. |
More Info |
| A431 | A431 cells were established from an epidermoid carcinoma in the skin / epi… | 0.1 mg, 0.2 mg, 0.5 mg | MBS201022 |
MYBIOSOURCE INC. |
More Info |
| A-443654 | Purity >98%. A-443654, a specific Akt inhibitor with Ki value of 160 pM, i… | 2 mg, 5 mg, 10 mg | MBS384086 |
MYBIOSOURCE INC. |
More Info |
| A-484954 | Purity >98%. A-484954 is a potent, selective inhibitor of eukaryotic longa… | 10 mg, 25 mg, 50 mg | MBS384087 |
MYBIOSOURCE INC. |
More Info |
| A549 | A549 cells are adenocarcinomic human alveolar basal epithelial cells. The… | 0.1 mg, 0.2 mg, 0.5 mg | MBS201023 |
MYBIOSOURCE INC. |
More Info |
| A66 | MW: 393.53 | 10 mg | MBS8506193 |
MYBIOSOURCE INC. |
More Info |
| A66 | Purity >98%. The S-enantiomer of A66 is a potent inhibitor of the p110alph… | 5 mg, 1 mL (in DMSO), 10 mg | MBS384089 |
MYBIOSOURCE INC. |
More Info |
| A66 | Purity 97%+. MW: 393.53 | 2 mg, 5 mg, 1ml/10mM (in DMSO) | MBS575616 |
MYBIOSOURCE INC. |
More Info |
| A-674563 | MW: 358.44 | 2 mg | MBS8506244 |
MYBIOSOURCE INC. |
More Info |
| A-674563 | Purity ≥98%. A-674563 is an Akt1 inhibitor with Ki of 11 nM, modest pot… | 1 mg, 2 mg, 5 mg | MBS578707 |
MYBIOSOURCE INC. |
More Info |
| A-674563 | Purity ≥98%. MW: 358.445 | 100 mg, 500 mg | MBS131746 |
MYBIOSOURCE INC. |
More Info |
| A-674563 | Purity >98%. A-674563 is a B / Akt inhibitor with an IC50 of 14 nM and als… | 5 mg, 1 mL (in DMSO), 10 mg | MBS384090 |
MYBIOSOURCE INC. |
More Info |
| A-769662 | Purity ≥98% by HPLC. Background: Cell-permeable. A potent AMPK activato… | 5 mg | MBS842018 |
MYBIOSOURCE INC. |
More Info |
| A-769662 | Purity >98%. A-769662 is a new activator of AMP-activated protein kinase (… | 5 mg, 10 mg, 1 mL (in DMSO) | MBS384092 |
MYBIOSOURCE INC. |
More Info |
| A77 1726 | Purity ≥98% by HPLC. Background: Physiologically active metabolite of t… | 5 mg, 25 mg | MBS842963 |
MYBIOSOURCE INC. |
More Info |
| A77-01 | Purity ≥98%. MW: 286.33 | 2 mg, 5 mg, 1ml/10mM (in DMSO) | MBS577536 |
MYBIOSOURCE INC. |
More Info |
| A77-01 | Purity ≥98%. MW: 286.338 | 100 mg, 500 mg | MBS130865 |
MYBIOSOURCE INC. |
More Info |
| A-803467 | Purity ≥98% (TLC). MW: 357.8 | 10 mg, 50 mg | MBS565381 |
MYBIOSOURCE INC. |
More Info |
| A-803467 | Purity ≥98% by TLC. Background: A-803467 is a potent, selective inhibit… | 5 mg, 25 mg | MBS842200 |
MYBIOSOURCE INC. |
More Info |
| A-803467 | Purity ≥98%. MW: 357.79 | 100 mg, 500 mg | MBS132100 |
MYBIOSOURCE INC. |
More Info |
| A-803467 | Purity ≥98%. MW: 357.79 | 1ml/10mM (in DMSO), 10 mg, 25 mg | MBS575739 |
MYBIOSOURCE INC. |
More Info |
| A-804598 | Purity >98%. A-804598 is a P2X7 selective, competitive antagonist with the… | 5 mg, 10 mg, 25 mg | MBS384094 |
MYBIOSOURCE INC. |
More Info |
| A83-01 | Purity >98% (TLC); NMR (Conforms). ALK inhibitor. Selective glycogen synth… | 5 mg, 25 mg | MBS515040 |
MYBIOSOURCE INC. |
More Info |
| A-83-01 | Purity 97%+. MW: 421.52 | 2 mg, 5 mg, 10 mg | MBS575483 |
MYBIOSOURCE INC. |
More Info |
| A-966492 | A-966492 is a highly potent and efficacious poly(ADP-ribose) polymerase (P… | 10 mg | MBS8506196 |
MYBIOSOURCE INC. |
More Info |
| A-966492 | Purity ≥98%. A-966492 is a novel and potent inhibitor of PARP1 and PARP… | 2 mg, 5 mg, 1ml/10mM (in DMSO) | MBS578914 |
MYBIOSOURCE INC. |
More Info |
| A-966492 | Purity ≥98%. MW: 324.359 | 100 mg, 500 mg | MBS132689 |
MYBIOSOURCE INC. |
More Info |
| A-966492 | Purity >98%. A-966492 displayed high potency against the poly(ADP-ribose)… | 5 mg, 1 mL (in DMSO), 10 mg | MBS384096 |
MYBIOSOURCE INC. |
More Info |
| A1120 | n/a | n/a | A3111 |
 MILLIPORE-SIGMA |
More Info |
| A 784168 | A 784168 is a potent TRPV1 antagonist, inhibiting human TRPV1 activation b… | 10 mg | A-345 |
 ALOMONE LABS |
More Info |
| A 784168 | A 784168 is a potent TRPV1 antagonist, inhibiting human TRPV1 activation b… | 25 mg | A-345 |
ALOMONE LABS |
More Info |
| A 784168 | A 784168 is a potent TRPV1 antagonist, inhibiting human TRPV1 activation b… | 5 mg | A-345 |
ALOMONE LABS |
More Info |
| A 784168 | A 784168 is a potent TRPV1 antagonist, inhibiting human TRPV1 activation b… | 50 mg | A-345 |
ALOMONE LABS |
More Info |
| A 967079 | A 967079 is a blocker of TRPA1 channels and has IC50 values of 67 and 289… | 10 mg | A-225 |
ALOMONE LABS |
More Info |
| A 967079 | A 967079 is a blocker of TRPA1 channels and has IC50 values of 67 and 289… | 100 mg | A-225 |
ALOMONE LABS |
More Info |
| A 967079 | A 967079 is a blocker of TRPA1 channels and has IC50 values of 67 and 289… | 25 mg | A-225 |
ALOMONE LABS |
More Info |
| A 967079 | A 967079 is a blocker of TRPA1 channels and has IC50 values of 67 and 289… | 250 mg | A-225 |
ALOMONE LABS |
More Info |
| A 967079 | A 967079 is a blocker of TRPA1 channels and has IC50 values of 67 and 289… | 5 mg | A-225 |
ALOMONE LABS |
More Info |
| A 967079 | A 967079 is a blocker of TRPA1 channels and has IC50 values of 67 and 289… | 50 mg | A-225 |
ALOMONE LABS |
More Info |
| A-192621 | A-192621 is a selective antagonist of ET-B endothelin receptors, inhibitin… | 1 mg | A-360 |
ALOMONE LABS |
More Info |
| A-192621 | A-192621 is a selective antagonist of ET-B endothelin receptors, inhibitin… | 10 mg | A-360 |
ALOMONE LABS |
More Info |
| A-192621 | A-192621 is a selective antagonist of ET-B endothelin receptors, inhibitin… | 25 mg | A-360 |
ALOMONE LABS |
More Info |
| A-192621 | A-192621 is a selective antagonist of ET-B endothelin receptors, inhibitin… | 5 mg | A-360 |
ALOMONE LABS |
More Info |
| A23187 | A23187 is a mobile-carrier Ca2+ ionophore and can cause cell activation, d… | 1 mg | A-600 |
ALOMONE LABS |
More Info |
| A23187 | A23187 is a mobile-carrier Ca2+ ionophore and can cause cell activation, d… | 10 mg | A-600 |
ALOMONE LABS |
More Info |
| A23187 | A23187 is a mobile-carrier Ca2+ ionophore and can cause cell activation, d… | 10 x 1 mg | A-600 |
ALOMONE LABS |
More Info |
| A23187 | A23187 is a mobile-carrier Ca2+ ionophore and can cause cell activation, d… | 5 mg | A-600 |
ALOMONE LABS |
More Info |
| A23187 | A23187 is a mobile-carrier Ca2+ ionophore and can cause cell activation, d… | 5 x 5 mg | A-600 |
ALOMONE LABS |
More Info |
| A-740003 | A-740003 is a potent and selective competitive antagonist of P2X7 receptor… | 10 mg | A-420 |
ALOMONE LABS |
More Info |
| A-740003 | A-740003 is a potent and selective competitive antagonist of P2X7 receptor… | 100 mg | A-420 |
ALOMONE LABS |
More Info |
| A-740003 | A-740003 is a potent and selective competitive antagonist of P2X7 receptor… | 25 mg | A-420 |
ALOMONE LABS |
More Info |
| A-740003 | A-740003 is a potent and selective competitive antagonist of P2X7 receptor… | 50 mg | A-420 |
ALOMONE LABS |
More Info |
| A-794278 | A-794278 is a potent and selective noncompetitive mGluR1 antagonist, actin… | 10 mg | A-435 |
ALOMONE LABS |
More Info |
| A-794278 | A-794278 is a potent and selective noncompetitive mGluR1 antagonist, actin… | 25 mg | A-435 |
ALOMONE LABS |
More Info |
| A-794278 | A-794278 is a potent and selective noncompetitive mGluR1 antagonist, actin… | 5 mg | A-435 |
ALOMONE LABS |
More Info |
| A-794278 | A-794278 is a potent and selective noncompetitive mGluR1 antagonist, actin… | 50 mg | A-435 |
ALOMONE LABS |
More Info |
| A-803467 | A-803467 is a potent and selective blocker of the TTX-resistant NaV1.8 cha… | 10 mg | A-105 |
ALOMONE LABS |
More Info |
| A-803467 | A-803467 is a potent and selective blocker of the TTX-resistant NaV1.8 cha… | 100 mg | A-105 |
ALOMONE LABS |
More Info |
| A-803467 | A-803467 is a potent and selective blocker of the TTX-resistant NaV1.8 cha… | 25 mg | A-105 |
ALOMONE LABS |
More Info |
| A-803467 | A-803467 is a potent and selective blocker of the TTX-resistant NaV1.8 cha… | 50 mg | A-105 |
ALOMONE LABS |
More Info |
| A-804598 | A-804598 is a potent and selective, competitive and high-affinity antagoni… | 10 mg | A-415 |
ALOMONE LABS |
More Info |
| A-804598 | A-804598 is a potent and selective, competitive and high-affinity antagoni… | 25 mg | A-415 |
ALOMONE LABS |
More Info |
| A-804598 | A-804598 is a potent and selective, competitive and high-affinity antagoni… | 5 mg | A-415 |
ALOMONE LABS |
More Info |
| A-804598 | A-804598 is a potent and selective, competitive and high-affinity antagoni… | 50 mg | A-415 |
ALOMONE LABS |
More Info |
| A-839977 | A-839977 is a potent and selective antagonist of P2X7 receptors, shown to… | 10 mg | A-470 |
ALOMONE LABS |
More Info |
| A-839977 | A-839977 is a potent and selective antagonist of P2X7 receptors, shown to… | 25 mg | A-470 |
ALOMONE LABS |
More Info |
| A-839977 | A-839977 is a potent and selective antagonist of P2X7 receptors, shown to… | 5 mg | A-470 |
ALOMONE LABS |
More Info |
| A-839977 | A-839977 is a potent and selective antagonist of P2X7 receptors, shown to… | 50 mg | A-470 |
ALOMONE LABS |
More Info |
| A-841720 | A-841720 is a potent and selective noncompetitive mGluR1 antagonist, actin… | 10 mg | A-440 |
ALOMONE LABS |
More Info |
| A-841720 | A-841720 is a potent and selective noncompetitive mGluR1 antagonist, actin… | 25 mg | A-440 |
ALOMONE LABS |
More Info |
| A-841720 | A-841720 is a potent and selective noncompetitive mGluR1 antagonist, actin… | 5 mg | A-440 |
ALOMONE LABS |
More Info |
| A-841720 | A-841720 is a potent and selective noncompetitive mGluR1 antagonist, actin… | 50 mg | A-440 |
ALOMONE LABS |
More Info |
| A-850002 | A-850002 inhibits mGluR1 in rat primary cerebellar granule neurons with an… | 10 mg | A-390 |
ALOMONE LABS |
More Info |
| A-850002 | A-850002 inhibits mGluR1 in rat primary cerebellar granule neurons with an… | 25 mg | A-390 |
ALOMONE LABS |
More Info |
| A-850002 | A-850002 inhibits mGluR1 in rat primary cerebellar granule neurons with an… | 5 mg | A-390 |
ALOMONE LABS |
More Info |
| A-850002 | A-850002 inhibits mGluR1 in rat primary cerebellar granule neurons with an… | 50 mg | A-390 |
ALOMONE LABS |
More Info |
| A-889425 | A-889425 blocks TRPV1 channels with an IC50 of 335 nM (rat) and 34 nM (hum… | 1 mg | A-195 |
ALOMONE LABS |
More Info |
| A-889425 | A-889425 blocks TRPV1 channels with an IC50 of 335 nM (rat) and 34 nM (hum… | 10 mg | A-195 |
ALOMONE LABS |
More Info |
| A-889425 | A-889425 blocks TRPV1 channels with an IC50 of 335 nM (rat) and 34 nM (hum… | 25 mg | A-195 |
ALOMONE LABS |
More Info |
| A-889425 | A-889425 blocks TRPV1 channels with an IC50 of 335 nM (rat) and 34 nM (hum… | 5 mg | A-195 |
ALOMONE LABS |
More Info |
| A-889425 | A-889425 blocks TRPV1 channels with an IC50 of 335 nM (rat) and 34 nM (hum… | 50 mg | A-195 |
ALOMONE LABS |
More Info |
| 293A | The HEK 293A cell line is an immortalized line of primary human embryonic… | 1 vial | ABI-TC1333 |
 ACCEGEN BIOTECH |
More Info |
| A10.7 | Derived from metastatic liver tumor (clinical stage IV). | 1 vial | ABC-TC533S |
ACCEGEN BIOTECH |
More Info |
| A-172 | Organ: brain Disease: glioblastoma. | 1 vial | ABC-TC0022 |
ACCEGEN BIOTECH |
More Info |
| A-204 | Human Muscle Rhabdomyosarcoma cell line. The A-204 cell line was establish… | 1 vial | ABC-TC445S |
ACCEGEN BIOTECH |
More Info |
| A2058 | Malignant melanoma, metastasis to lymph node. | 1 vial | ABC-TC0023 |
ACCEGEN BIOTECH |
More Info |
| A-253 | The A253 line is one of thirteen to be isolated and partially characterize… | 1 vial | ABC-TC0024 |
ACCEGEN BIOTECH |
More Info |
| A375 | This line was derived from a 54 year old female with malignant melanoma. | 1 vial | ABC-TC0026 |
ACCEGEN BIOTECH |
More Info |
| A-427 | A-427 cell line was established from the lung carcinoma of a 52-year-old C… | 1 vial | ABC-TC1339 |
ACCEGEN BIOTECH |
More Info |
| A-431 | The epidermoid carcinoma cell line A-431, derived from an 85-year-old fema… | 1 vial | ABC-TC0030 |
ACCEGEN BIOTECH |
More Info |
| A-498 | Established from the kidney carcinoma of a 52-year-old man in 1973. | 1 vial | ABC-TC0031 |
ACCEGEN BIOTECH |
More Info |
| A549 | A549 cell line was initiated in 1972 by D.J. Giard, et al. Through explant… | 1 vial | ABC-TC0032 |
ACCEGEN BIOTECH |
More Info |
| A6 | Frog (Xenopus laevis) cell line derived from kidney. Lifespan: infinite. | 1 vial | ABC-TC020S |
ACCEGEN BIOTECH |
More Info |
| A-673 | Tissue: muscle Disease: rhabdomyosarcoma. | 1 vial | ABC-TC0034 |
ACCEGEN BIOTECH |
More Info |
| A-704 | Human kidney adenocarcinoma. Derived from 78-year-old male. Does not produ… | 1 vial | ABC-TC0021 |
ACCEGEN BIOTECH |
More Info |
| A-72 | Canine Golden Retriever tumour. Derived from tumour of thigh (unknown hist… | 1 vial | ABC-TC0036 |
ACCEGEN BIOTECH |
More Info |
| A9 | Mouse C3H / An areolar and adipose tissue. Derivative of L929 selected in… | 1 vial | ABC-TC0037 |
ACCEGEN BIOTECH |
More Info |